Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase i trial

Rastislav Bahleda, Christophe Massard, Jean Charles Soria, Hassan Izzedine, Ariel Cohen, Stéphane Ederhy

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Tyrosine kinase inhibitors (TKI) or monoclonal antibodies targeting EGFR, HER2 or VEGFR receptors have demonstrated substantial clinical benefit in patients with advanced breast cancer, colon cancer, head and neck cancer, non-small cell lung cancer, and renal cell carcinoma. Nevertheless, these drugs have some target related adverse effects, particularly cardiovascular toxicities. We report here the case of a patient included in a phase I trial of a new compound, a tyrosine kinase inhibitor targeting HER1, HER2, HER4 and VEGFR2. The patient developed during this treatment an acute and transient left ventricular systolic dysfunction. Careful management of this adverse effect allowed the patient to continue therapy and to achieve a major partial response.

    Original languageEnglish
    Pages (from-to)350-352
    Number of pages3
    JournalInvestigational New Drugs
    Volume28
    Issue number3
    DOIs
    Publication statusPublished - 1 Jun 2010

    Keywords

    • Antiangiogenic
    • Cancer
    • Cardiotoxicity
    • Tyrosine kinase inhibitors

    Cite this